top of page
Our Science
T-cell engagers (TCEs) are alternatives to mAbs that actively recruit T-cells to kill cancer cells.
TCEs hold a lot of promise, however there can be toxicity issues associated with immune over- stimulation & on-target, off-tumor effects, as well as issues tumor uptake and retention in solid tumors.
The Trident platform unlocks the potential of T-cell engagers for solid tumor immunotherapy. The platform is based on an engineered human scaffold, allowing us to combine both the specificity of antibody therapy with tumor penetration and retention. The Trident platform is designed to activate only in the tumor microenvironment to further shield patients from off- target toxicity.
September 14, 2024
Poseidon news coming soon
bottom of page